Potential Therapies to Protect the Aging Heart Against Ischemia/Reperfusion Injury.

aging cardioprotection ischemia/reperfusion injury mitochondria senolytics

Journal

Frontiers in cardiovascular medicine
ISSN: 2297-055X
Titre abrégé: Front Cardiovasc Med
Pays: Switzerland
ID NLM: 101653388

Informations de publication

Date de publication:
2021
Historique:
received: 03 09 2021
accepted: 29 10 2021
entrez: 6 12 2021
pubmed: 7 12 2021
medline: 7 12 2021
Statut: epublish

Résumé

Despite important advances in the treatment of myocardial infarction that have significantly reduced mortality, there is still an unmet need to limit the infarct size after reperfusion injury in order to prevent the onset and severity of heart failure. Multiple cardioprotective maneuvers, therapeutic targets, peptides and drugs have been developed to effectively protect the myocardium from reperfusion-induced cell death in preclinical studies. Nonetheless, the translation of these therapies from laboratory to clinical contexts has been quite challenging. Comorbidities, comedications or inadequate ischemia/reperfusion experimental models are clearly identified variables that need to be accounted for in order to achieve effective cardioprotection studies. The aging heart is characterized by altered proteostasis, DNA instability, epigenetic changes, among others. A vast number of studies has shown that multiple therapeutic strategies, such as ischemic conditioning phenomena and protective drugs are unable to protect the aged heart from myocardial infarction. In this Mini-Review, we will provide an updated state of the art concerning potential new cardioprotective strategies targeting the aging heart.

Identifiants

pubmed: 34869687
doi: 10.3389/fcvm.2021.770421
pmc: PMC8639870
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

770421

Informations de copyright

Copyright © 2021 Díaz-Vesga, Zúñiga-Cuevas, Ramírez-Reyes, Herrera-Zelada, Palomo, Bravo-Sagua and Riquelme.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Eur Heart J. 2020 Aug 14;41(31):2974-2982
pubmed: 32006431
J Eval Clin Pract. 2019 Oct;25(5):754-760
pubmed: 30485597
Nature. 2020 Jul;583(7814):127-132
pubmed: 32555459
Cardiology. 2014;128(2):209-19
pubmed: 24818643
Sci Rep. 2020 Feb 19;10(1):2896
pubmed: 32076073
Nature. 2018 Sep;561(7721):45-56
pubmed: 30185958
Cardiovasc Drugs Ther. 2018 Apr;32(2):165-168
pubmed: 29582211
Oxid Med Cell Longev. 2020 Aug 3;2020:9219825
pubmed: 32832010
Am J Cardiol. 2017 Aug 15;120(4):522-526
pubmed: 28645475
Basic Res Cardiol. 2017 Nov 15;113(1):2
pubmed: 29143177
Basic Res Cardiol. 2020 Nov 13;115(6):69
pubmed: 33188438
Comput Math Methods Med. 2021 Aug 9;2021:6415275
pubmed: 34422094
Nat Commun. 2019 Oct 21;10(1):4731
pubmed: 31636264
Cell Metab. 2021 Sep 7;33(9):1853-1868.e11
pubmed: 34418352
Science. 2016 Oct 28;354(6311):472-477
pubmed: 27789842
FASEB Bioadv. 2020 Mar 20;2(5):304-314
pubmed: 32395703
Heart. 2018 Mar;104(5):370-376
pubmed: 29092917
J Transl Med. 2018 Apr 27;16(1):112
pubmed: 29703217
Aging (Albany NY). 2020 Oct 13;12(19):19809-19827
pubmed: 33049718
J Cell Mol Med. 2020 Nov;24(21):12272-12284
pubmed: 33022900
Eur J Pharmacol. 2018 Aug 15;833:314-319
pubmed: 29935170
J Pineal Res. 2018 Aug;65(1):e12490
pubmed: 29570845
Circ Res. 2012 Apr 27;110(9):1226-37
pubmed: 22539756
Cardiovasc Drugs Ther. 2020 Sep 26;:
pubmed: 32979174
Cancer Res. 2013 Aug 15;73(16):5253-65
pubmed: 23774215
J Cachexia Sarcopenia Muscle. 2017 Jun;8(3):349-369
pubmed: 28432755
Cardiovasc Res. 2020 Sep 1;116(11):1835-1849
pubmed: 32384145
Basic Res Cardiol. 2018 Aug 17;113(5):39
pubmed: 30120595
Mech Ageing Dev. 2018 Mar;170:2-9
pubmed: 28688962
J Am Coll Cardiol. 2011 Jan 4;57(1):9-17
pubmed: 21185495
Eur Heart J. 2018 Sep 21;39(36):3393-3395
pubmed: 29722801
EBioMedicine. 2019 Sep;47:446-456
pubmed: 31542391
Mutat Res Rev Mutat Res. 2020 Apr - Jun;784:108309
pubmed: 32430098
Nat Commun. 2014 Dec 18;5:5863
pubmed: 25519492
Ann N Y Acad Sci. 2000 Jun;908:99-110
pubmed: 10911951
Aging Cell. 2016 Oct;15(5):973-7
pubmed: 26864908
EBioMedicine. 2019 Feb;40:554-563
pubmed: 30616998
Circulation. 2016 Aug 23;134(8):574-5
pubmed: 27550967
Antioxid Redox Signal. 2015 May 1;22(13):1146-61
pubmed: 25330141
Nat Rev Cardiol. 2018 Apr;15(4):203-214
pubmed: 29143812
Oxid Med Cell Longev. 2016;2016:3480637
pubmed: 26788246
JACC CardioOncol. 2020 Mar 17;2(1):97-109
pubmed: 34396213
Annu Rev Pharmacol Toxicol. 2021 Jan 6;61:779-803
pubmed: 32997601
Pharmacol Rev. 2014 Oct;66(4):1142-74
pubmed: 25261534
Cell Death Dis. 2021 Jul 2;12(7):665
pubmed: 34215721
JMIR Res Protoc. 2020 Sep 23;9(9):e19456
pubmed: 32965237
Br J Pharmacol. 2020 Dec;177(23):5252-5269
pubmed: 31430831
Nat Rev Cardiol. 2020 Dec;17(12):773-789
pubmed: 32620851
Best Pract Res Clin Anaesthesiol. 2011 Sep;25(3):305-17
pubmed: 21925398
Aging Cell. 2020 Apr;19(4):e13128
pubmed: 32196916
FASEB J. 2006 Jul;20(9):1543-5
pubmed: 16793872
EBioMedicine. 2018 Oct;36:18-28
pubmed: 30279143
Nat Metab. 2019 Nov;1(11):1074-1088
pubmed: 31799499
Proc Natl Acad Sci U S A. 2015 Nov 17;112(46):E6301-10
pubmed: 26578790
Basic Res Cardiol. 2018 Jan 15;113(2):9
pubmed: 29335904
Thromb Haemost. 2015 Mar;113(3):441-51
pubmed: 25631625
Sci Rep. 2018 May 29;8(1):8258
pubmed: 29844497
Front Physiol. 2020 Apr 29;11:366
pubmed: 32411013
Cardiovasc Res. 2021 Jan 02;:
pubmed: 33386841
Nat Rev Immunol. 2010 Dec;10(12):826-37
pubmed: 21088683
Nat Rev Cardiol. 2017 Nov;14(11):637-653
pubmed: 28660894
Aging Cell. 2020 Feb;19(2):e13096
pubmed: 31944526
Cell Syst. 2016 Oct 26;3(4):374-384.e4
pubmed: 27746093
Cardiology. 2016;133(2):128-33
pubmed: 26536214
Lancet. 2019 Oct 19;394(10207):1415-1424
pubmed: 31500849
Front Cardiovasc Med. 2019 Apr 02;6:31
pubmed: 31001540
J Cardiovasc Pharmacol Ther. 2020 May;25(3):240-250
pubmed: 31645107
FASEB J. 2017 Sep;31(9):4153-4167
pubmed: 28592638
Oxid Med Cell Longev. 2018 Feb 25;2018:9173436
pubmed: 29636855
Cardiovasc Res. 2017 May 1;113(6):564-585
pubmed: 28453734
Indian Heart J. 2020 Nov-Dec;72(6):619-622
pubmed: 33357657
Aging Cell. 2019 Jun;18(3):e12945
pubmed: 30920115
EMBO J. 2019 Mar 1;38(5):
pubmed: 30737259

Auteurs

Magda C Díaz-Vesga (MC)

Programa de Fisiología y Biofísica, Instituto de Ciencias Biomédicas (ICBM), Facultad de Medicina, Universidad de Chile, Santiago, Chile.
Grupo de Investigación en Ciencias Básicas y Clínicas de la Salud, Pontificia Universidad Javeriana de Cali, Cali, Colombia.
Advanced Center for Chronic Disease (ACCDiS), Facultad de Ciencias Químicas y Farmacéuticas, Facultad de Medicina, Universidad de Chile, Santiago, Chile.

Úrsula Zúñiga-Cuevas (Ú)

Advanced Center for Chronic Disease (ACCDiS), Facultad de Ciencias Químicas y Farmacéuticas, Facultad de Medicina, Universidad de Chile, Santiago, Chile.

Andrés Ramírez-Reyes (A)

Advanced Center for Chronic Disease (ACCDiS), Facultad de Ciencias Químicas y Farmacéuticas, Facultad de Medicina, Universidad de Chile, Santiago, Chile.

Nicolas Herrera-Zelada (N)

Advanced Center for Chronic Disease (ACCDiS), Facultad de Ciencias Químicas y Farmacéuticas, Facultad de Medicina, Universidad de Chile, Santiago, Chile.

Iván Palomo (I)

Thrombosis Research Center, Faculty of Health Sciences, Universidad de Talca, Talca, Chile.
Interuniversity Center for Healthy Aging, Chile.

Roberto Bravo-Sagua (R)

Advanced Center for Chronic Disease (ACCDiS), Facultad de Ciencias Químicas y Farmacéuticas, Facultad de Medicina, Universidad de Chile, Santiago, Chile.
Interuniversity Center for Healthy Aging, Chile.
Instituto de Nutrición y Tecnología de los Alimentos (INTA), Universidad de Chile, Santiago, Chile.

Jaime A Riquelme (JA)

Advanced Center for Chronic Disease (ACCDiS), Facultad de Ciencias Químicas y Farmacéuticas, Facultad de Medicina, Universidad de Chile, Santiago, Chile.
Interuniversity Center for Healthy Aging, Chile.

Classifications MeSH